Determination of orally coadministered nadolol and its deuterated analogue in human serum and urine by gas chromatography with selected-ion monitoring mass spectrometry.
A cartridge serum and urine extraction procedure of the beta-adrenergic antagonist, nadolol, employing a cross-linked styrene-divinyl benzene macroreticular resin is described. Samples were analyzed as the silylated derivative by gas chromatography-mass spectrometry (GC-MS) using selected-ion monitoring. When nadolol was orally coadministered with its deuterated analogue, relative bioavailability could be demonstrated with six or fewer subjects. Employing a base-deactivated GC phase, the limit of detection is 1 ng and 0.5 ng/mL of serum for nadolol and the deuterated analogue, respectively. For levels of less than 10 ng/mL, the respective coefficients of variation are 4 and 2%. For concentrations of greater than 10 ng/mL, the CV is 1% for nadolol and nadolol-d9.
D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000032:analysis* / Q000097:blood / Q000652:urine; D001682:Biological Availability; D055598:Chemical Phenomena; D002621:Chemistry; D003903:Deuterium; D008401:Gas Chromatography-Mass Spectrometry / Q000379:methods; D006801:Humans; D007700:Kinetics; D009248:Nadolol; D011412:Propanolamines / Q000032:analysis* / Q000097:blood / Q000652:urine; D012996:Solutions; D013607:Tablets
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D012996:Solutions; D013607:Tablets; D009248:Nadolol; D003903:Deuterium